Zevra Therapeutics (ZVRA) EBITDA Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) reported EBITDA Margin of 144.05% for Q1 2026, up 17033.0% on a YoY basis from N/an in Q1 2025, and up 428.41% quarter-over-quarter from 27.26% in Q4 2025.
Zevra Therapeutics (ZVRA) EBITDA Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics has reported EBITDA Margin for 8 years, with the latest figure at 144.05% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 17033.0% year-over-year to 144.05%; the trailing twelve-month figure through Mar 2026 stood at 4.44% (up 17300.0% YoY), and the FY2025 full-year result was 58.93%, up 30869.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 144.05%, up from 27.26% in the prior quarter.
- The five-year high for EBITDA Margin was 144.05% in Q1 2026, with the low at 739.0% in Q3 2024.
- Historically, EBITDA Margin has averaged 225.05% across 5 years, with a median of 117.31% in 2023.
- Annual changes were most pronounced in 2023 — EBITDA Margin plunged 52643 bps — and 2025, when it jumped 75489 bps.
- Zevra Therapeutics' EBITDA Margin stood at 424.67% in 2022, then soared by 72 bps to 117.31% in 2023, then declined by 9 bps to 128.34% in 2024, then soared by 121 bps to 27.26% in 2025, then jumped by 428 bps to 144.05% in 2026.
- The last three EBITDA Margin figures came in at 144.05% (Q1 2026), 27.26% (Q4 2025), and 15.9% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 144.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144.05% |
| Dec 31, 2025 | 27.26% |
| Sep 30, 2025 | 15.90% |
| Jun 30, 2025 | -274.48% |
| Mar 31, 2025 | -26.28% |
| Dec 31, 2024 | -128.34% |
| Sep 30, 2024 | -739.00% |
| Jun 30, 2024 | -540.80% |
| Mar 31, 2024 | -602.53% |
| Dec 31, 2023 | -117.31% |
| Sep 30, 2023 | -530.71% |
| Jun 30, 2023 | -73.81% |
| Mar 31, 2023 | -404.00% |
| Dec 31, 2022 | -424.67% |
| Sep 30, 2022 | -4.28% |
| Jun 30, 2022 | -100.00% |
| Mar 31, 2022 | -46.89% |
| Dec 31, 2021 | -110.07% |
| Sep 30, 2021 | -113.08% |
| Jun 30, 2021 | 48.67% |